Vancouver, British Columbia–(Newsfile Corp. – August 26, 2026) – Gold Runner Exploration Inc. (CSE: GRUN) (FSE: CE70) (“Gold Runner” or the “Company“) is pleased to announce results from the Company’s annual general meeting held on August 25, 2026. All agenda items were completed, and where required, approved by the shareholders of the Company, including: Receiving the audited annual financial

By M. Marin NYSE: TRC READ THE FULL TRC RESEARCH REPORT 2Q26 arguably reflects benefits of cost containments, growth & optimization measures Tejon Ranch Company (NYSE: TRC) reported 2Q26 results that arguably reflect the benefits of its cost containment measures. Recent measures include streamlining efforts expected to deliver $2.0 million in annual cost savings. Moreover, combined with a greater than

By David Bautz, PhD NASDAQ: LABT READ THE FULL LABT RESEARCH REPORT Business Update Finalizing Preparations for Phase 2a Trial of Nu-3 in infected diabetic foot ulcers Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) is continuing final preparations for the upcoming Phase 2a clinical trial of Nu-3 in patients with infected diabetic foot ulcers (iDFUs). The trial will evaluate three different doses of

Why a good junior gold company can be right about the rock and still cost you years Every investor relations professional in junior gold knows the meeting. The drilling is good. The grade is real. The jurisdiction is fine. The story has improved in every measurable way for three straight years. And the stock has gone nowhere. The reflex is

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following encouraging durability data from